These complex immune landscapes suggest distinct roles for CTNNB1 and TP53 mutations in shaping the tumor immune microenvironment and emphasize the need for further validation in larger cohorts to clarify their predictive values in immunotherapy. The gene discussed is CTNNB1; the disease is neoplasm.